Patent Assignment Details
NOTE:Results display only for issued patents and published applications.
For pending or abandoned applications please consult USPTO staff.
|
Reel/Frame: | 044965/0539 | |
| Pages: | 4 |
| | Recorded: | 02/19/2018 | | |
Attorney Dkt #: | PAT057048-US-PCT |
Conveyance: | ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). |
|
Total properties:
1
|
|
Patent #:
|
NONE
|
Issue Dt:
|
|
Application #:
|
15753045
|
Filing Dt:
|
02/15/2018
|
Publication #:
|
|
Pub Dt:
|
08/30/2018
| | | | |
Title:
|
PHARMACEUTICAL COMBINATIONS COMPRISING (A) THE CYCLIN DEPENDENT KINASE 4/6 (CDK4/6) INHIBITOR LEE011 (=RIBOCICLIB), AND (B) THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) INHIBITOR ERLOTINIB, FOR THE TREATMENT OR PREVENTION OF CANCER
|
|
Assignee
|
|
|
LICHTSTRASSE 35 |
BASEL, SWITZERLAND 4056 |
|
Correspondence name and address
|
|
CINDY KLEPACKY
|
|
ONE HEALTH PLAZA
|
|
EAST HANOVER, NJ 07936
|
Search Results as of:
06/27/2024 12:05 AM
If you have any comments or questions concerning the data displayed,
contact
PRD / Assignments at 571-272-3350. v.2.6
Web interface last modified:
August 25, 2017 v.2.6
|